ArticleTrials2022

Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study.

Sina M Coldewey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.